NATCO announces tentative approval to its ANDA for Trabectedin (generic for Yondelis®)

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces today that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis® ) for the 1mg/vial presentation. According to industry sales data, Yondelis® generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market. *All brand names and trademarks are the property of their respective owners.

The release as fetched from its publisher. natcopharma.co.in ↗